1. Home
  2. ITRN vs URGN Comparison

ITRN vs URGN Comparison

Compare ITRN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ituran Location and Control Ltd.

ITRN

Ituran Location and Control Ltd.

HOLD

Current Price

$50.75

Market Cap

881.7M

Sector

Technology

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$17.49

Market Cap

922.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRN
URGN
Founded
1994
2004
Country
Israel
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
881.7M
922.1M
IPO Year
2005
2016

Fundamental Metrics

Financial Performance
Metric
ITRN
URGN
Price
$50.75
$17.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$62.50
$29.29
AVG Volume (30 Days)
88.5K
801.8K
Earning Date
03-05-2026
03-02-2026
Dividend Yield
4.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$12.38
$119.37
Revenue Next Year
$8.21
$64.79
P/E Ratio
$16.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.23
$3.42
52 Week High
$51.76
$30.00

Technical Indicators

Market Signals
Indicator
ITRN
URGN
Relative Strength Index (RSI) 58.82 35.17
Support Level $34.52 $15.86
Resistance Level N/A $20.44
Average True Range (ATR) 1.89 1.15
MACD -0.00 -0.16
Stochastic Oscillator 92.21 6.87

Price Performance

Historical Comparison
ITRN
URGN

About ITRN Ituran Location and Control Ltd.

Ituran Location and Control Ltd is a provider of location-based services. The company operates in two segments, namely Telematics services and Telematics products. The Telematics services segment consists of regionally-based stolen vehicle recovery (SVR) services, fleet management services, and value-added services comprised of personal locater services and concierge services. The Telematics product segment consists of short and medium-range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location and automatic vehicle identification. Its geographical segments include Israel, Brazil, and Others. The company derives maximum revenue from Israel.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: